<pad> In the Costa Rica trial, ATP efficacy against 12-month persistent infection with any of 3 types (HPV 31, 33, or 45) was 44.5% (95% CI = 17.5–63.1); for individual types, efficacy was found for HPV 31 (45.7%; 95% CI = 8.2–68.6) (161).HPV2 ImmunogenicityFemales Aged 9–25 YearsData on immunogenicity are available from the phase II and phase efficacy III trials conducted in females aged 15–25 years and immunogenicity trials conducted in females aged 9–14 years (10,158,167).</s>